Tag: SRNE

Finance

Traders Are Watching : Energous Corporation (NASDAQ:WATT), Nike, Inc. (NYSE:NKE), Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Sotherly Hotels Inc. (NASDAQ:SOHO), PPL Corporation (NYSE:PPL)

Energous Corporation (NASDAQ:WATT), the developer of WattUp™, a disruptive wire-free charging technology for electronic devices that provides power at a distance with complete mobility under full software control, on AUG 22 announced it has issued Inducement Awards and Performance Awards of restricted stock units to our Senior Vice President of Engineering pursuant to his offer letter. Energous Corporation (NASDAQ:WATT) belongs to Consumer Goods sector. Its … Continue reading Traders Are Watching : Energous Corporation (NASDAQ:WATT), Nike, Inc. (NYSE:NKE), Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Sotherly Hotels Inc. (NASDAQ:SOHO), PPL Corporation (NYSE:PPL)

Chris Lewis
Finance

Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Sorrento Therapeutics Inc (NASDAQ:SRNE) announced in a press release that the National Institutes of Health (NIH) has provided funding for the development of bispecific antibodies. Two small business grants from the NIH will allow Sorrento to use its antibody conjugation technology platform to develop antibodies for two of the NIH’s anti-bacterial immunotherapies. Sorrento’s pipeline also shows promise in anti-infectives and auto-immune diseases. Sorrento Therapeutics Inc … Continue reading Healthcare Decliners: Sorrento Therapeutics (NASDAQ:SRNE), Fibrocell Science (NYSEMKT:FCSC), TG Therapeutics (NASDAQ:TGTX), CombiMatrix (NASDAQ:CBMX)

Mark Doerr
Finance

Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, … Continue reading Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Jayne Crisman
Finance

Healthcare Gainers: Health Insurance Innovations Inc (NASDAQ:HIIQ), Biostar Pharmaceuticals (NASDAQ:BSPM), Applied Genetic Technologies (NASDAQ:AGTC), Versartis Inc (NASDAQ:VSAR), Sorrento Therapeutics (NASDAQ:SRNE)

Research analysts at Dougherty & Co assumed coverage on shares of Health Insurance Innovations Inc (NASDAQ:HIIQ) in a report released on Friday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock. Health Insurance Innovations Inc (NASDAQ:HIIQ) stock performance was 5.89% in last session and finished the day at $10.43. Traded volume was 30,114.00million shares in the last session and the average volume of … Continue reading Healthcare Gainers: Health Insurance Innovations Inc (NASDAQ:HIIQ), Biostar Pharmaceuticals (NASDAQ:BSPM), Applied Genetic Technologies (NASDAQ:AGTC), Versartis Inc (NASDAQ:VSAR), Sorrento Therapeutics (NASDAQ:SRNE)

John Bellich
Finance

Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Fate Therapeutics Inc (NASDAQ:FATE) recently issued a statement that it has enrolled it first patient for the second phase of this study. The primary aim of the PUMA study is to assess the efficacy and safety of PROHEMA in a randomized, controlled environment for patients that are under treatment for hematopoietic stem cell or HSC transplantation for hematologic malignancies. Fate Therapeutics Inc (NASDAQ:FATE) stock performance … Continue reading Biotech Gainers: Fate Therapeutics Inc (NASDAQ:FATE), ZIOPHARM Oncology (NASDAQ:ZIOP), Uniqure NV (NASDAQ:QURE), Sorrento Therapeutics (NASDAQ:SRNE)

Colin Pettis